Postoperative concurrent chemoradiotherapy with paclitaxel/carboplatin chemotherapy in patients with high risk early stage cervical cancer.
Phase 1
- Conditions
- terine cervical cancer
- Registration Number
- JPRN-UMIN000017231
- Lead Sponsor
- Osaka University Hospital. Dept of Obstetrics and Gynecology.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Early-stage cervical cancer patients without pelvic lymph nodes metastasis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly paclitaxel/carboplatin chemoradiotherapy in early stage cervix cancer.
- Secondary Outcome Measures
Name Time Method The efficacy of postoperative paclitaxel/carboplatin chemoradiotherapy in early stage cervix cancer.